• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The Macro View – Health, Economics, and Politics and the Big Picture. What I Am Watching Here And Abroad.
August 18, 2022 Edition-----The main issue, probably of the year, is the increasing tension across the Taiwan Strait with all sorts of worries about how conflict can be avoided and prosperity maintained at a reasonable level as tensions continue. And hopefully ease.The impact of climate change in Europe is really becoming obvious and worrying. I am not sure just how a realistic response is possible in any reasonable time.In OZ the PM has come back after a week off to have the Chinese Ambassador tell us we are a vassal and to just shut up and behave. Astonishing and serious stuff IMVHO.-----Major Issues.-----https://www.smh...
Source: Australian Health Information Technology - August 18, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs

Fight Aging! Newsletter, January 11th 2021
This study demonstrates the potential of a natural (o-Vanillin) and a synthetic (RG-7112) senolytic compounds to remove senescent IVD cells, decrease SASP factors release, reduce the inflammatory environment and enhance the IVD matrix production. Removal of senescent cells, using senolytics drugs, could lead to improved therapeutic interventions and ultimately decrease pain and a provide a better quality of life of patients living with intervertebral disc degeneration and low back pain. From Ying Ann Chiao of Oklahoma Medical Research Foundation: Mitochondrial dysfunction plays a central role in aging and cardiovasc...
Source: Fight Aging! - January 10, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Biopharma Leaders Unite To Stand With Science
NEW YORK, September 8, 2020 — The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines. All nine CEOs signed the following pledge: We, the unders...
Source: Johnson and Johnson - September 8, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Fight Aging! Newsletter, September 10th 2018
In conclusion, HSC ageing is characterised by reduced self-renewal, myeloid and platelet HSC skewing, and expanded clonal haematopoiesis that is considered a preleukaemic state. The underlying molecular mechanisms seem to be related to increased oxidative stress due to ROS accumulation and DNA damage, which are influenced by both cell- and cell non-autonomous mechanisms such as prolonged exposure to infections, inflammageing, immunosenescence, and age-related changes in the HSC niche. Thus, HSC ageing seems to be multifactorial and we are only beginning to connect all the dots. The Price of Progress or the Waste...
Source: Fight Aging! - September 9, 2018 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Fight Aging! Newsletter, May 16th 2016
In this study the authors demonstrate that, as in many other cases, the methodology of delivery matters just as much as the details of the cells used: Retinal and macular degenerative diseases affect millions of people worldwide. Similar to other neurodegenerative diseases, there are no effective treatments that can stop retinal degeneration or restore degenerative retina. Recent advances in stem cell technology led to development of novel cell-based therapies, some are already in phase I/II clinical trials. Studies from our group and others suggest that human bone marrow-derived mesenchymal stem cells (hBM-MSC) m...
Source: Fight Aging! - May 15, 2016 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

It is Vital to Accelerate Development of Means to Effectively Treat the Causes of Aging
In the long sweep of human history, there has never been an age in which advocacy could have made as big a difference as advocacy for aging research can make today. The scientific community stands at the gates of rejuvenation, of the effective medical control over the causes of aging. The forms of cell and tissue damage that distinguish old tissues from young tissues are cataloged. The consensus position in the research community is that accumulation of this damage causes aging. Rejuvenation therapies capable of repairing, preventing, or working around the damage of aging are not in the clinic yet, but are at various stage...
Source: Fight Aging! - May 9, 2016 Category: Research Authors: Reason Tags: Activism, Advocacy and Education Source Type: blogs

PhRMA Report: Over 5400 Medicines in Development and 70% are First in Class
According to report released by PhRMA, companies have more than 5,400 medicines in development globally, and more than 70% of therapies in the pipeline are potentially first-in-class and could offer patients new treatment options, and a notable number of potential therapies target diseases with limited treatment options such as ALS and rare diseases.  A breakdown of their report offers insight into the various medicines in development for different diseases and populations.    Older Americans  America’s biopharmaceutical research companies are developing 465 new medicines that target the 10 leading chronic conditi...
Source: Policy and Medicine - April 24, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs